1D·

Ouch but important

After it became known that Hims & Hers $HIMS (-6.34%) wants to copy the Novo pill $NOVO B (+10.5%) and will probably deliberately infringe the patent, I am now leaving the position. I don't want to have anything to do with this, it has broken my trust.

06.02

Hims & Hers Health

Sold x34 at €18.20

€618.80

57.91%

20 Comments

Tom@Tomtom12

Ditto...something like that has no place in the depot

•

Investor19@Investor19

I can't really understand that. Three weeks ago you made a very positive post about Hims.
I understand that the pill has "broken your trust". But the fact that Hims medicines are designed very closely to those of the competition is nothing really new.

•

Mi(t)chel@Mi-t-chel

@Investor19 That is correct and I stand by it. I always try to rethink my position and take all the information into account. That's why the exchange here is important to me. The share has not bottomed out in the last three weeks. In addition, it makes a difference whether I copy medication in times of shortage or deliberately outside of it. It was an issue with the syringes. Now both $NOVO B and $LLY are under attack, and with quasi copycat preparations in tablet form. That makes me rethink things.

•

Tom M.@Lumimyrsky

good chance of buying more. I definitely understand your thinking. But I think it's very well thought out and Novo would have very little chance in a lawsuit. Novo is simply angry that they have ended the cooperation and are tripping themselves up every 2 weeks

•

Klein-Anleger@Klein-Anleger

Hims does not directly copy the Novo pill. By personalizing the pill for each individual patient (for example by adding B12, which means it is not a direct copy), the company is operating in a legal grey area, but this makes it possible to enter a new business segment much more cheaply.
Hims will thus penetrate even further into the segments of the traditional healthcare industry and drive vertical integration. I don't expect a Danish company to win in court against a US company because of a legal gray area.
@Aktienfox What do you think?

•

Mi(t)chel@Mi-t-chel

@Klein-Anleger well.... think that $LLY is not so happy with the copycat preparations either.

••

Olli@Olli68

@Klein-Anleger How do you want to personalize a mass-produced product like a pill?

•

Aktienfox@Aktienfox

@Klein-Anleger I doubt that a lawsuit will be successful... as you described! They had the chance to bring a lawsuit against hins for a long time, which they delayed. In addition, they are in the gray area as long as this remains no more than a threat. However, GLP-1 would be normalized out of the business model, i.e. semaglutide, should this be dropped at some point. But liraglutide remains available! Hims reported on this weeks ago and showed statistics confirming that users would also take a worse product, i.e. liraglutide, which they are allowed to sell!

•

Tom@tom_finance

@Olli68 that is a key part of Ham's business model. Personalized medicines

•

Klein-Anleger@Klein-Anleger

@Olli68 Sorry, that was poorly expressed. I meant that the pill does not contain only GLP1 directly, but is modified and combined. This makes it less legally vulnerable.
But basically, this is actually the business model of selling personalized therapies and medicines tailored to the customer...

•

Mi(t)chel@Mi-t-chel

@Olli68 it's just too tricky for me to be honest

••

Olli@Olli68

@Klein-Anleger The problem will be that they use semaglutide for this. And only Novo Nordisk is allowed to do that because they have the patent. Compounding means that they have to change the drug for a single person because they are allergic to an ingredient in the original, for example.
Apart from that, they are clearly violating trademark law with their press release by naming Wegovy. They already have a lawsuit pending against Eli Lilly for trademark infringement and misleading advertising.

•

Tom M.@Lumimyrsky

@Aktienfox But maybe now is also the chance. To finally get away from this whole GLP-1 issue. That has always hovered over the share. It would be nice if all the other TOP areas were given more attention now

•

Aktienfox@Aktienfox

So that was obvious :) is a smart move

•

Pascal@Pacco93

I honestly don't know how people can keep talking up this share. Of course the share will rise again at some point, but there are 473838 better alternatives 🤔

•

OberstvonGatow@OberstvonGatow

@Pacco93 and what would they be?

•

Wravo@Wravo

I understand the reason, but then Hims should have been sold much earlier, they are doing almost the same game as with the syringeb

•

Olli@Olli68

Respekt 👍

••

David@Redfox77

@Olli68 Yes, in a community with a naturally large number of opportunists, that's remarkable.

••

nassimcanim@nassimcanim

i could well imagine that the 2nd deal for the renewed cooperation fell through and they thought novo's share price was going down anyway and they are under extreme pressure... let's put even more pressure on them maybe with a little sympathy towards eli lilly. everything is still pretty positive

••